Glyscend Inc
Glyscend Inc., located in Baltimore, MD, is pioneering innovative treatments for Type 2 Diabetes and obesity through a novel class of gut-targeted polymer therapies. Their dynamic barrier approach aims to deliver the benefits of metabolic surgery without the invasiveness, utilizing orally administered drugs that replicate the physiological effects of bariatric procedures.
With a team experienced in gastroenterology, metabolism, polymer chemistry, and drug development, Glyscend has contributed to over 25 FDA-approved products, including several first-in-class therapies. Their latest advancements include the enrollment of patients in clinical trials for their first-in-class oral polymeric drug candidate, GLY-200, aimed at treating metabolic diseases.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.

